The U.S. Food and Drug Administration on Friday approved the first pill designed specifically to treat postpartum depression.
Zuranolone, trade name Zurzuvae—a steroid that works to rapidly repair dysregulated neuronal networks in the brain—is only the second drug approved for the condition, thought to affect one in seven women. The other, Zulresso (brexanolone), was approved by the FDA in 2019. But it’s administered via IV over time and requires a hospital admission, making it inaccessible to many women.
